Disease Markers / 2018 / Article / Tab 2

Review Article

The Clinical Utility of Circulating Epstein-Barr Virus DNA Concentrations in NK/T-Cell Lymphoma: A Meta-Analysis

Table 2

Characteristics of the included studies.

StudyDesignInclusion periodNMedian or mean ageAnn Arbor stageSampleCut-off valueTreatment strategyExtractable survival outcomesMedian follow-up (months)

Lei et al. [21]R1995–20012661yaI–IVPlasma600CT/RT/CT → RTOS13 (4.5–24.3)
Kim et al. [9]R2004–20074748.5yaI–IVWhole bloodMedianNROSNR
Suzuki et al. [10]P2004–20073255yaI–IVPlasma1000CT/RT/CCRT/RT → CTOSNR
Wang et al. [11]P2007–20096939yaI–IIPlasma5000RT/RT → CTOS, PFS32
Y Ito 2012 (1)PNR2646.5yaNRPlasma10E5CTOS, CR, and ORRNR
Y Ito 2012 (2)PNR2646.5yaNRWhole blood1000CTOS, CR, and ORRNR
Kwong et al. [12]P2005–20125452.5yaI–IVPlasma0CTOSNR
Liu et al. [13]R2011–201410940yaI–IVPlasma500NRPFS, ORRNR
Kim et al. [14]R2005–201310248yaI–IVWhole blood0CT/CCRT/CT → RTOS, PFS47.2 (30–65.5)
Wang et al. [6]P2008–20146847yaI–IIPlasma00CT → RTOS, PFS, and CR32 (2–76)
Lim et al. [15]R2009–20142744yaI–IVWhole blood0CCRTOS, PFS36.9 (1.6–75.4)
Liang et al. [15]R2007–20121343.5yaI–IVPlasmaMedianCT/RT/CCRT/CT → RT/RT → CTOSNR
Yang et al. [17]R2006–20168141yaI–IVPlasma500CT/CT → RT/RT → CTOS,PFS21 (1–123)
Zhang et al. [23]P2010–20148538.66ybI–IVPlasma0CT → RTOS, PFS, CR, and ORRNR
Liang et al. [18]P2010–20153248yaIII–IVWhole blood5000CTOS, PFS, and ORRNR

R: retrospective study; P: prospective study; NR: not reported; N: number of participants; pre-DNA: pretreatment EBV-DNA; post-DNA: posttreatment EBV-DNA; CT: chemotherapy; RT: radiotherapy; CCRT: concurrent chemoradiotherapy; OS: overall survival; PFS: progression-free survival; CR: complete response; ORR: overall response rate. aMedian age. bMean age.